The role and efficacy of Pazopanib

Pazopanib is indicated for the first-line treatment of adults with advanced renal cell carcinoma (RCC) and patients who have previously received cytokine therapy for advanced disease. It is also indicated for the treatment of adult patients with select subtypes of advanced soft tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months of (neo)adjuvant therapy. But efficacy and safety have only been established in certain STS histological tumor subtypes.

Pazopanibis a potent, selective, broad-spectrum, multi-target receptor tyrosine kinase inhibitor, includingVEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α/β and c-kit. The overall disease control rate for patients with advanced renal cell carcinoma was 82%. The most common adverse events include increased transaminase activity, diarrhea, fatigue, nausea, hair discoloration, and hypertension. According to an interim analysis, adverse reactions led to discontinuation in 5% of patients. Preliminary data suggest the drug has additional activity in ovarian cancer with a comparable adverse effect profile

PazopanibThe original drug has been launched in China and has entered the scope of Class B medical insurance, but reimbursement is limited to patients who meet the indications. The price of each box may be around 3,000 yuan. The price of pazopanib original drug specifications200mg*30 tablets marketed overseas may be around 1,000 RMB per box (the price may fluctuate due to exchange rates). There are also pazopanib generic drugs produced in other countries. The price of 200mg*30 tablets produced by Bangladesh pharmaceutical factory may be around 500 yuan per box (the price may fluctuate due to the exchange rate), which is cheaper. The pharmaceutical ingredients of generic drugs are basically the same as those of domestic and foreign original drugs.